Literature DB >> 19920152

The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin.

Moh'd A Salameh1, Jessica L Robinson, Duraiswamy Navaneetham, Dipali Sinha, Benjamin J Madden, Peter N Walsh, Evette S Radisky.   

Abstract

The amyloid precursor protein (APP) is a ubiquitously expressed transmembrane adhesion protein and the progenitor of amyloid-beta peptides. The major splice isoforms of APP expressed by most tissues contain a Kunitz protease inhibitor domain; secreted APP containing this domain is also known as protease nexin 2 and potently inhibits serine proteases, including trypsin and coagulation factors. The atypical human trypsin isoform mesotrypsin is resistant to inhibition by most protein protease inhibitors and cleaves some inhibitors at a substantially accelerated rate. Here, in a proteomic screen to identify potential physiological substrates of mesotrypsin, we find that APP/protease nexin 2 is selectively cleaved by mesotrypsin within the Kunitz protease inhibitor domain. In studies employing the recombinant Kunitz domain of APP (APPI), we show that mesotrypsin cleaves selectively at the Arg(15)-Ala(16) reactive site bond, with kinetic constants approaching those of other proteases toward highly specific protein substrates. Finally, we show that cleavage of APPI compromises its inhibition of other serine proteases, including cationic trypsin and factor XIa, by 2 orders of magnitude. Because APP/protease nexin 2 and mesotrypsin are coexpressed in a number of tissues, we suggest that processing by mesotrypsin may ablate the protease inhibitory function of APP/protease nexin 2 in vivo and may also modulate other activities of APP/protease nexin 2 that involve the Kunitz domain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19920152      PMCID: PMC2804352          DOI: 10.1074/jbc.M109.057216

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Genes, cloned cDNAs, and proteins of human trypsinogens and pancreatitis-associated cationic trypsinogen mutations.

Authors:  J M Chen; C Ferec
Journal:  Pancreas       Date:  2000-07       Impact factor: 3.327

2.  Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification.

Authors:  Itai Yanai; Hila Benjamin; Michael Shmoish; Vered Chalifa-Caspi; Maxim Shklar; Ron Ophir; Arren Bar-Even; Shirley Horn-Saban; Marilyn Safran; Eytan Domany; Doron Lancet; Orit Shmueli
Journal:  Bioinformatics       Date:  2004-09-23       Impact factor: 6.937

3.  Variability of the canonical loop conformations in serine proteinases inhibitors and other proteins.

Authors:  W Apostoluk; J Otlewski
Journal:  Proteins       Date:  1998-09-01

4.  Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of Alzheimer's amyloid beta-protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI): engineering of inhibitors with altered specificities.

Authors:  A J Scheidig; T R Hynes; L A Pelletier; J A Wells; A A Kossiakoff
Journal:  Protein Sci       Date:  1997-09       Impact factor: 6.725

5.  Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression.

Authors:  M M Webber; S T Quader; H K Kleinman; D Bello-DeOcampo; P D Storto; G Bice; W DeMendonca-Calaca; D E Williams
Journal:  Prostate       Date:  2001-04       Impact factor: 4.104

6.  Human cationic trypsinogen. Role of Asn-21 in zymogen activation and implications in hereditary pancreatitis.

Authors:  M Sahin-Tóth
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

7.  Secretion of protease nexin-II/amyloid beta protein precursor by human colorectal carcinoma cells and its modulation by cytokines/growth factors and proteinase inhibitors.

Authors:  K Seguchi; H Kataoka; H Uchino; K Nabeshima; M Koono
Journal:  Biol Chem       Date:  1999-04       Impact factor: 3.915

8.  Protease nexin II interactions with coagulation factor XIa are contained within the Kunitz protease inhibitor domain of protease nexin II and the factor XIa catalytic domain.

Authors:  K O Badellino; P N Walsh
Journal:  Biochemistry       Date:  2000-04-25       Impact factor: 3.162

9.  AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis.

Authors:  Feng Xu; Mary Lou Previti; Marvin T Nieman; Judianne Davis; Alvin H Schmaier; William E Van Nostrand
Journal:  J Neurosci       Date:  2009-04-29       Impact factor: 6.167

10.  Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.

Authors:  Ken-ichi Takayama; Shuichi Tsutsumi; Takashi Suzuki; Kuniko Horie-Inoue; Kazuhiro Ikeda; Kiyofumi Kaneshiro; Tetsuya Fujimura; Jinpei Kumagai; Tomohiko Urano; Yoshiyuki Sakaki; Katsuhiko Shirahige; Hironobu Sasano; Satoru Takahashi; Tadaichi Kitamura; Yasuyoshi Ouchi; Hiroyuki Aburatani; Satoshi Inoue
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

View more
  23 in total

Review 1.  Biochemical and structural insights into mesotrypsin: an unusual human trypsin.

Authors:  Moh'd A Salameh; Evette S Radisky
Journal:  Int J Biochem Mol Biol       Date:  2013-09-13

2.  Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.

Authors:  Alexandre P Alloy; Olumide Kayode; Ruiying Wang; Alexandra Hockla; Alexei S Soares; Evette S Radisky
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

3.  An Acrobatic Substrate Metamorphosis Reveals a Requirement for Substrate Conformational Dynamics in Trypsin Proteolysis.

Authors:  Olumide Kayode; Ruiying Wang; Devon F Pendlebury; Itay Cohen; Rachel D Henin; Alexandra Hockla; Alexei S Soares; Niv Papo; Thomas R Caulfield; Evette S Radisky
Journal:  J Biol Chem       Date:  2016-11-03       Impact factor: 5.157

4.  Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure.

Authors:  Jyotica Batra; Jessica Robinson; Alexei S Soares; Alan P Fields; Derek C Radisky; Evette S Radisky
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

5.  The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity.

Authors:  Moh'd A Salameh; Alexei S Soares; Alexandra Hockla; Derek C Radisky; Evette S Radisky
Journal:  Biochem J       Date:  2011-11-15       Impact factor: 3.857

6.  Inactivation of mesotrypsin by chymotrypsin C prevents trypsin inhibitor degradation.

Authors:  Vanda Toldi; András Szabó; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2020-02-03       Impact factor: 5.157

7.  Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases.

Authors:  Itay Cohen; Si Naftaly; Efrat Ben-Zeev; Alexandra Hockla; Evette S Radisky; Niv Papo
Journal:  Biochem J       Date:  2018-04-16       Impact factor: 3.857

8.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

9.  Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin.

Authors:  Itay Cohen; Matt Coban; Anat Shahar; Banumathi Sankaran; Alexandra Hockla; Shiran Lacham; Thomas R Caulfield; Evette S Radisky; Niv Papo
Journal:  J Biol Chem       Date:  2019-01-30       Impact factor: 5.157

10.  Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Authors:  Itay Cohen; Olumide Kayode; Alexandra Hockla; Banumathi Sankaran; Derek C Radisky; Evette S Radisky; Niv Papo
Journal:  Biochem J       Date:  2016-03-08       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.